OppenheimerFunds Inc. grew its holdings in shares of Bioverativ Inc (NASDAQ:BIVV) by 147.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,434,200 shares of the biotechnology company’s stock after buying an additional 853,853 shares during the quarter. OppenheimerFunds Inc.’s holdings in Bioverativ were worth $77,332,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the company. State Treasurer State of Michigan purchased a new position in Bioverativ during the third quarter worth about $2,323,000. Oakbrook Investments LLC purchased a new position in Bioverativ during the third quarter worth about $327,000. APG Asset Management N.V. purchased a new position in Bioverativ during the third quarter worth about $3,048,000. Nationwide Fund Advisors purchased a new position in Bioverativ during the third quarter worth about $17,617,000. Finally, Boston Advisors LLC purchased a new position in Bioverativ during the third quarter worth about $877,000. Hedge funds and other institutional investors own 99.97% of the company’s stock.
Bioverativ Inc (NASDAQ BIVV) opened at $104.74 on Friday. The firm has a market cap of $11,335.38 and a PE ratio of 38.09. Bioverativ Inc has a 52 week low of $48.14 and a 52 week high of $104.75.
Bioverativ (NASDAQ:BIVV) last released its earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.01. The firm had revenue of $328.70 million for the quarter, compared to analysts’ expectations of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. analysts expect that Bioverativ Inc will post 3.83 EPS for the current fiscal year.
Several research analysts recently weighed in on the stock. Argus restated a “hold” rating on shares of Bioverativ in a report on Wednesday, January 24th. Credit Suisse Group restated a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Piper Jaffray Companies cut shares of Bioverativ from an “overweight” rating to a “neutral” rating in a report on Monday, January 22nd. Finally, Royal Bank of Canada boosted their price target on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a report on Thursday, January 18th. Thirteen analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Bioverativ has a consensus rating of “Hold” and a consensus target price of $63.15.
COPYRIGHT VIOLATION NOTICE: This news story was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://transcriptdaily.com/2018/02/25/oppenheimerfunds-inc-has-77-33-million-stake-in-bioverativ-inc-bivv.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.